NEWS

An international delegation discovers BioArk in Monthey

A delegation of around fifty international life sciences specialists visited BioArk in Monthey on 24 April. It was an opportunity to get to know the Valais ecosystem in this field, with presentations by Valais start-ups and a conference by the Idiap research institute on artificial intelligence. The visit to the Valais was organised as part of Swiss Biotech Day, one of the biggest life sciences events in Switzerland.

An international delegation discovers BioArk in Monthey Read More »

BioArk invites you to take part in the online event Biotechgate Digital Partnering

Biotechgate Digital Partnering is an online event that runs four times a year to support the business development & licensing of Pharma, Biotech, Medtech and Digital Health companies. Biotechgate Digital Partnering usually hosts over 1,000 representatives from leading life science companies and investors from around the globe, including big pharma, biotech start-ups and corporate investors.
The next edition of the popular five-day international conference series will be held virtually from May 13 to 17, 2024, and is free to attend.

BioArk invites you to take part in the online event Biotechgate Digital Partnering Read More »

The HES-SO Valais-Wallis strengthens its national positioning in Life Sciences

The HES-SO Valais-Wallis School of Engineering is today unveiling a major change in the way it promotes its educational offerings and research and innovation skills in the life sciences sector.
Over the past few years, the Swiss biopharmaceutical and food industries have undergone a rapid shift towards life sciences. Driven by innovation, collaboration and a commitment to health, wellbeing and sustainability, a number of partner companies of the Swiss College of Engineering (HEI), such as Debiopharm and Lonza, have massively expanded these business areas to meet the needs of the economy.

The HES-SO Valais-Wallis strengthens its national positioning in Life Sciences Read More »

Orio Therapeutics Secures CHF 500’000 Pre-Seed Funding to Fuel the Development of Cardioprotective Therapy

Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, today announced the successful closure of a CHF 500,000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionizing treatment approaches for patients suffering from debilitating conditions.

Orio Therapeutics Secures CHF 500’000 Pre-Seed Funding to Fuel the Development of Cardioprotective Therapy Read More »

ten23 health and SHL Medical announce a strategic partnership agreement for integrated services

ten23 health, based in Basel and at the BioArk Visp, and SHL Medical, a world-leading provider of drug delivery devices, announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.

ten23 health and SHL Medical announce a strategic partnership agreement for integrated services Read More »

ten23 health’s expansion in Visp will be operational by en 2024 !

Swiss CDMO ten23 health has announced in its press release that its large-scale pre-filled syringe, cartridge and vial aseptic filling line 2 (VIVA2) in Visp (Switzerland) will be GMP operational by end 2024! Located near by our Visp technological site of BioArk, the ten23 Health’s expansion, previously first announced in June, 2022 is  now completing

ten23 health’s expansion in Visp will be operational by en 2024 ! Read More »

Start typing and press enter to search

Scroll to Top